Military wastewater surveillance expands without privacy safeguards

What it does

This bill requires the Department of Defense to run a two-year pilot program testing wastewater surveillance systems at four or more military installations to detect drug use and infectious diseases among service members. The Secretary of Defense must report findings and recommendations to Congress within 90 days of the program's end, using existing DoD resources and authorities.

Why we flagged it

The bill's core function is to authorize a two-year pilot program for wastewater-based epidemiology at DoD installations, focused on force health protection and readiness monitoring. It is a straightforward public-health and military-readiness measure, not a deregulation, subsidy, or commemorative act.

What the text implies

• Wastewater surveillance collects health and drug-use data on service members without explicit individual consent; the bill does not specify data retention, access controls, or limits on secondary use of collected information.
• The term 'covered drug' excludes drugs approved by FDA within the past 20 years, potentially leaving newer pharmaceutical substances unmonitored even if they pose force-readiness risks.
• The bill grants the Secretary broad discretion to determine 'appropriate technologies' and 'uniform data systems' without congressional oversight of technical standards, potentially enabling surveillance expansion beyond the pilot scope.
• No explicit privacy safeguards, data-minimization requirements, or service-member notification provisions are included; military personnel may not know their wastewater is being analyzed for drug metabolites.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The program may improve military readiness and public health by identifying disease outbreaks and substance-abuse trends among service members, benefiting force health. However, wastewater surveillance of military personnel raises privacy concerns—service members' drug use and health data are collected without individual consent, and the scope of data retention and downstream use is not specified in the bill.

Who stands to gain

• wastewater surveillance technology vendors
• laboratory and diagnostic service providers
• data analytics and epidemiology contractors

Named in the bill

Department of Defense, Secretary of Defense, Congressional Defense Committees, Military departments, Armed Forces, Controlled Substances Act (section 202), Federal Food, Drug, and Cosmetic Act (section 505)

Where it stands

• Nov 7, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Nov 7, 2025 — Referred to Senate Committee on Armed Services · Congress.gov: “Read twice and referred to the Committee on Armed Services”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

2 lobbying clients named this bill on 4 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $120,000 in lobbying spend. A filing names 23 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 41% of bills with at least one filing.

Elissa Slotkin, the sponsor, reported $43,550 in PAC receipts in the 2026 cycle.

• American Security Fund — $60,000 on 2 filings
• American Security Fund — $60,000 on 2 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.